摘要
目的:探讨益气活血汤(Yiqi Huoxue decoction)对肺癌细胞恶性生物学行为的抑制作用及其机制。方法:以不同浓度益气活血汤含药血清(5%、10%、15%)处理人肺癌A549细胞,CCK-8(Cell Counting Kit-8)法、Transwell小室实验、流式细胞术、Western blot法和定量逆转录聚合酶链式反应(qRT-PCR)法研究益气活血汤含药血清对细胞增殖、迁移和侵袭能力、细胞凋亡、第10染色体同源丢失性磷酸酶-张力蛋白(phosphatase and tensin homolog deleted on chromosome ten,PTEN)蛋白和miR-21表达的影响。结果:与无药血清组相比较,不同剂量的益气活血汤含药血清处理后,A549细胞存活率降低、迁移和侵袭能力下降;细胞凋亡率上升、细胞内PTEN mRNA及其蛋白表达增加、miR-21表达下降,且10%含药血清组的效果最佳。转染miR-21 mimics后,A549细胞中miR-21表达上调,PTEN蛋白表达下调;10%含药血清处理后PTEN蛋白表达上调。结论:益气活血汤可有效抑制人肺癌A549细胞恶性细胞生物学行为,且可能与miR-21/PTEN信号通路的调控有关。
AIM:To investigate the inhibitory effect of Yiqi Huoxue decoction on the malignant biological behavior of lung cancer cells and its mechanism.METHODS:Human lung cancer A549 cells were treated with different doses of Yiqi Huoxue Decoction serum(5%,10%,15%).CCK-8 assay,transwell chamber experiment,flow cytometry,Western blot and qRT-PCR method were used to study the effect of different doses of Yiqi Huoxue Decoction-containing serum to cell proliferation,cell migration and invasion,cell apoptosis,PTEN protein and miR-21 expression.RESULTS:Compared with the drug-free serum group,survival rate,migration and invasion ability of A549 cells decreased after treatment with different doses of drug-containing serum.The apoptosis rate of A549 cells increased,PTEN mRNA and the expression of its protein increased,the expression of miR-21 decreased,and the medium-dose(10%)drug-containing serum group had the best effect.After the transfection of miR-21 mimics,miR-21 expression was up-regulated,while PTEN protein expression was down-regulated in cells.PTEN protein expression was up-regulated after treatment with medium-dose(10%)drug-containing serum.CONCLUSION:Yiqi Huoxue Decoction can effectively inhibit the malignant cell biological behavior of human lung cancer A549 cells and may be related to the regulation of the miR-21/PTEN signaling pathway.
作者
杨国良
胡丹丹
徐一凯
楼黎明
YANG Guoliang;HU Dandan;XU Yikai;LOU Liming(Oncology Department of Integrated Chinese and Western Medicine Hospital of Zhejiang Province,Hangzhou 310002,Zhejiang,China;Department of Respiratory Diseases,the Third Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310005,Zhejiang,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2020年第5期512-518,共7页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
浙江省自然科学基金青年项目(LQ18H270002)
浙江省中医药科技计划项目(2016ZA108)
浙江省中医药科技计划项目(2015ZB084)
浙江中医药大学校级科研基金项目(2019ZG18)。
